Refining the use of endocrine therapy for ductal carcinoma in situ

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1249-1251

  Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; EDITORIAL; EXCISION; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAMMOGRAPHY; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RISK REDUCTION; UNITED STATES; BREAST TUMOR; CARCINOMA IN SITU; DRUG EFFECT; FEMALE; NOTE; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84862268079     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.5514     Document Type: Editorial

References (22)

1. SEER Program of the National Cancer Institute: Cancer of the female breast (invasive): Trends in SEER incidence and U.S. mortality using the Joinpoint Regression Program. http://seer.cancer.gov/csr/1975-2007/results- merged/sect-04-breast.pdf
2. Wapnir IL, Dignam JJ, Fisher B, et al: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478-488, 2011
3. Lee LA, Silverstein MJ, Chung CT, et al: Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg 192:416-419, 2006 (Pubitemid 44344203)
4. Katz SJ, Lantz PM, Janz NK, et al: Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 23:5526-5533, 2005
5. Allred DC, Anderson SJ, Paik S, et al: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP Protocol B-24. J Clin Oncol 30:1268-1273, 2012
6. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999 (Pubitemid 29271743)
7. Cuncins-Hearn A, Boult M, Babidge W, et al: National Breast Cancer Audit: Ductal carcinoma in situ management in Australia and New Zealand. ANZ J Surg 77:64-68, 2007 (Pubitemid 46150944)
8. Yen TW, Hunt KK, Mirza NQ, et al: Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100:942-949, 2004 (Pubitemid 38222854)
9. Nakhlis F, Lazarus L, Hou N, et al: Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg 201:688-694, 2005 (Pubitemid 41539760)
10. Zujewski JA, Harlan LC, Morrell DM, et al: Ductal carcinoma in situ: Trends in treatment over time in the US. Breast Cancer Res Treat 127:251-257, 2011
11. Allred DC, Bryant J, Land S, et al: Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. Breast Cancer Res Treat 5:S36, 2002
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
13. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005 (Pubitemid 41672231)
14. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86-92, 2003 (Pubitemid 37046374)
15. Rhodes A, Jasani B, Balaton AJ, et al: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53:688-696, 2000
16. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
17. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005 (Pubitemid 41339000)
18. Goss PE, Ingle JN, Alés-Martí;nez JE, et al: Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381-2391, 2011
19. Vogel VG, Costantino JP, Wickerham DL, et al: Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project breast cancer chemoprevention trials. J Natl Cancer Inst Monogr 2010:181-186, 2010
20. Tuttle TM, Jarosek S, Habermann EB, et al: Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol 27:1362-1367, 2009
21. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A populationbased study. Int J Radiat Oncol Biol Phys 56:1038-1045, 2003 (Pubitemid 36794035)
22. Lostumbo L, Carbine NE, Wallace J: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010:CD002748, 2010